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Introduction
Selection of T lymphocytes capable of distinction between self and non-self is a key maturation process of the cellular immune system. This study differentiates between T-ALL blasts with (SR) and without a selection-related (NSR) immunophenotype. Knowledge about T cell differentiation and the associated immunophenotypes is increasing rapidly. [1] [2] [3] Originating from lymphoid stem cells in the bone marrow (BM), T precursor cells migrate to the thymus. In the thymic cortex cells acquire a CD1
+ and/or CD4 + CD8 + double-positive (DP) phenotype that is associated with a unique biology. As selection takes place, cortical thymocytes proliferate extensively and 98% of the thymocytes undergo apoptosis. 3 This suggests a different biological behavior of the selection-related T-lineage ALL cases (CD1 + or DP) with respect to apoptosis compared to non-selection-related T-ALL. Here, it is investigated whether this particular biology might also influence the therapeutic response of cases with a SR T-ALL phenotype.
Materials and methods

Patients
From 25 January 1985 to 17 August 1994, 741 patients were recruited in the German COALL multicenter trials. To be enrolled in the COALL protocols patients had to be over 1 year and under 18 years of age.
Diagnosis and therapy
T-ALL was diagnosed on the basis of Ͼ25% lymphoblasts in the BM by microscopy and the presence of classical T cell surface markers (see below). At diagnosis the size of lymph nodes, liver and spleen, as well as testicular involvement were assessed by physical examination. The presence of a mediastinal mass was verified by chest X-ray. Routine blood counts were recorded. Patients with Ͼ5 cells/l in the CSF with lymphoblasts were diagnosed to have CNS involvement. Patients with T-ALL were treated on the high risk arm of the protocols COALL-85, -89, -92, [4] [5] [6] which apart from minor modifications represents the same intensive therapy consisting of six blocks. On day −7 intravenous daunorubicin (36 mg/m 2 ) was given. 2 ) days 1-7 and 15-22. CNS prophylaxis consisted of irradiation with an age-adjusted dosage and four concomitant injections of methotrexate as well as 4 weeks of oral 6-mercaptopurine. During the first 3 months of therapy five doses of intrathecal methotrexate were given.
Complete remission (CR) was defined as the absence of leukemic blasts in peripheral blood, BM (Ͻ5%) and CSF, relapse as recurrence of leukemic blasts at any location. Death from disease was due to relapse or non-response of the leukemia, death from complication was due to therapy-related complications.
Immunophenotyping and immunological subclassification
Immunophenotyping was done on BM by standard immunofluorescence microscopy (indirect labelling) and FACS analysis using fluorescence-labelled, monoclonal antibodies to CD epitopes. In 13 cases, immunophenotyping was done on peripheral blood samples only. A panel of markers (B-lineage: CD19, CD20, CD22, CD24, CD38, CD10, cylgM; T-lineage: CD2, CD4, CD8, CD7, CD1a, CD3, CD5; myeloid lineage: CD13, CD33, CD14; non-lineage specific: HLA-DR) was used to assign acute leukemias to T-, B-or myeloid lineage similar to the first and second screen panel proposed by the European Group for the Immunological Characterization of Leukemias (EGIL) classification. 7 According to this panel 102/741 COALL cases were diagnosed as T-ALL (13.8%). Cytoplasmatic CD3 staining could not uniformally be used for classification in this study since it was not standardized until 1992. T-ALL was classified as SR (Table 1) , if at least one or both of two criteria for CD1 expression (1) or evidence for CD4 +
CD8
+ DP leukemic blasts (II) were fulfilled. Since double-staining for CD4 CD8 DP cells was not established until 1992 within the COALL study group, a formula was needed to define CD4 CD8 DP cells. The formulas for criterion II were originally based on theoretical considerations to detect DP cells and to simultaneously eliminate CD3
CD4
+ monocytes and CD3 − CD8 + NK cells. The formulas were then evaluated by the comparison with the results of children treated at the university hospital of Dü sseldorf, in whom CD4 and CD8 double staining had been performed. T-ALL was classified as DP when more than 30% of the cells were double-positive. Neither false-positive nor false-negative results were obtained by using the formula compared to the results of CD4 and CD8 double staining by direct FACS analysis. Thus the formulas appeared to be suitable for the detection of DP cells.
Marker information was considered sufficient for classification on the basis of CD1, CD3, CD4 and CD8. Immunophenotyping with sufficient information for classification was available in 83/102 cases. The NSR (non-selection-related) group is defined as all phenotypes that are not SR. Blast phenotypes were classified as SR or NSR irrespective of aberrant marker expression.
To exclude the possibility that some of the immature NSR cases might represent AML or AUL TdT, HLA-DR, CD38, CD13 and CD33 staining was evaluated. There were 13 immature NSR cases. TdT staining was performed in 6/13 immature NSR cases and found positive (Ͼ30%) in four cases. In the remaining nine cases none showed HLA-DR or CD38 expression. Both HLA-DR and CD38 are associated with acute undifferentiated leukemia. 7 CD13 and/or CD33 staining was performed in seven of the nine remaining cases and there was no case with Ͼ10% staining with either marker. All immature cases were CD2 and/or CD7 positive. Thus, on the basis of a (Table 2) .
Statistical analysis
Differences in clinical presentation and percentage of CD2 expression between groups were compared using the Student t-test (P values Ͻ0.05 were considered statistically significant). The Kaplan-Meier method was used to calculate 5-year eventfree survival (EFS) rates. Events were defined as failure to achieve CR, relapse, and death. Differences between the immunological subgroups were calculated with the two-sided log-rank test. Multivariate regression analysis on the effect of SR/NSR classification on EFS relied on the Cox proportional hazards model to adjust for patient prognostic characteristics.
Results
Immunological classification and immunophenotype of subgroups
Thirty-nine of 83 cases were classified as SR phenotype. In 18 cases classification as SR was based on criterion I alone, in 12 on II alone and nine cases on both criteria. Using the conventional classification 29/83 cases were classified as midthymocyte which is the immunophenotype most closely related to the SR phenotype. Thirty-five of 83 cases were classified as NSR phenotype. By the conventional classification 37 cases were classified as 'non-midthymocyte' taking the early (n = 22) and late thymocyte phenotype (n = 15) together. Seventeen of 83 cases in the conventional classification could not be allocated to any of the subgroups.
Clinical presentation of patients with SR and NSR phenotype at diagnosis
The NSR and SR groups did not significantly differ in respect to age at diagnosis and initial leukocyte count. In addition, no 
CD2 expression related to immunological subgroup and outcome
Only a small number of patients (n = 15) showed a CD2-negative phenotype (Ͻ30% expression), so that it was not possible to test CD2 as an independent risk factor. Mean percentages of CD2 expression were compared between SR and NSR subgroups and between cases with and without events. Cases with events showed a significantly decreased CD2 expression compared to cases in CCR (40.4 ± 36.4 vs 60.9 ± 29.8, P = 0.02). However, CD2 expression was not significantly higher in the SR group (62.6 ± 31.2 s.d.) compared to NSR (49.3 ± 33.8).
CD10 expression related to outcome
CD10 assays were performed in 82 T-ALL cases and found positive (Ͼ30% expression) in 15/82 (18.2%). The 5-year EFS of these 15 CD10 + cases was 0.66 ± 0.12 which was not significantly different from the overall outcome.
Clinical outcome
The overall outcome for T-ALL (5-year EFS) in the entire cohort (n = 102) was 0.72 ± 0.05. The outcome in the SR and NSR group (n = 83) was 0.76 ± 0.05 (5-year EFS). There was no significant difference in outcome between the entire cohort (n = 102) and the cases that were not included in the SR/NSR classification (n = 19). Events in the SR group were five deaths from disease. In the NSR group there were 13 deaths from disease and two deaths from complications. Figure 1 represents the standard Kaplan-Meier analysis showing a significant difference between SR and NSR (P = 0.01). A multivariate analysis (Cox regression) was conducted to simultaneously evaluate the prognostic influence of SR/NSR phenotype as well as age, sex, liver and spleen size, CNS involvement, initial leukocyte count, percentage of blasts and presence of Figure 1 Kaplan-Meier analysis of 5-year EFS for immunophenotypical T-ALL subgroups in the COALL studies according to the SR/NSR classification. enlarged lymph nodes. SR/NSR phenotype remained a significant predictor of EFS (P = 0.04). Among the other variables CNS involvement also showed a significant effect (P = 0.04).
In the conventional early/mid/late thymocyte classification 5-year EFS was 0.83 ± 0.07 for midthymocyte, 0.68 ± 0.10 for early and 0.65 ± 0.12 for late thymocyte phenotype. The difference seen with midthymocyte (corresponding to SR) vs combined early/late thymocyte (corresponding to NSR) did not reach statistical significance.
Discussion
We define immunological subtypes by phenotypical evidence for a crucial biological feature of T cell development, selection. Emphasis is put on the detection of the SR CD1 +
CD4
+ CD8 + phenotype. In the conventional classification more than 30% expression is required for a marker to be positive. This threshold is lowered to 10% for CD1a expression (SR) as this marker is very lineage specific and thus reliable in discrimination between SR (CD1a + ) and NSR (CD1a − ) phenotype. Rather than looking at single CD3, CD4, CD8 expression the sum of CD4 and CD8 percentages is always correlated to the percentage of CD3 cells. This correlation facilitates the discrimination between SR (CD4 CD8 double positive) and NSR (CD4 or CD8 positive) phenotypes. Applied to the COALL studies, there are six cases with CD1a expression between 10-30% and three cases with evidence of a DP phenotype as defined by correlation to CD3. In the conventional classification, these nine cases are classified as early or late or cannot be classified at all. By the classification suggested here, these cases were identified as SR phenotype and showed an improved outcome.
Immunological subgroups of T-ALL based on the conventional classification had shown some prognostic significance [8] [9] [10] in earlier studies. The ALL Berlin-Frankfurt-Mü nster (BFM) 86 study was the first to observe a T-ALL subgroup of CD1a
+ phenotype with a significantly improved outcome. 11 The Children's Cancer Group (CCG) has shown a CD2 + subgroup with a favorable 12 and a subgroup of CD2 −
CD5
− CD7 + pro-thymocyte phenotype with an unfavorable outcome. 13 In the BFM and CCG studies, children with T-ALL received different risk-adjusted protocols of differing intensity (according to age, leukocyte count, lymphomatous features). Therefore, outcome in different subgroups might be influenced by the different types of protocols administered. The analysis of outcome in T-ALL subgroups may be more reliable in the COALL studies, because all children with T-ALL were treated on the high-risk arm of the protocol irrespective of other risk factors.
The question comes to mind why a SR phenotype should be associated with a better prognosis than a NSR. During T cell selection the death of unselected thymocytes occurs by apoptosis. Cortical thymocytes are extremely sensitive to glucocorticoid-induced apoptosis 3 and express high levels of FAS.
14 Induction of FAS-L has recently been shown to be a mechanism (autocrine suicide) by which apoptosis is induced in T leukemia cell lines in vitro. 15 In the BFM 86 trial, the T-ALL subset with favorable prognosis (comparable to the SR phenotype) showed an excellent response to prednisone, 11 which may be the result of glucocorticoid-induced apoptosis. CD2-mediated signals have been proposed to render blasts susceptible to apoptosis. 12 However, it is unlikely that CD2 plays a central part in selection as CD2 is dispensable for T cell selection. 3, 16 In SR blasts, CD2-independent mechanisms might be responsible for improved response as CD2 expression is not significantly increased in the SR group. The percentage of CD10 + T-ALL cases in our analysis was similar to that of the large T-ALL study by Uckun et al 12 (19.5% ). Neither study shows prognostic significance of CD10 expression in childhood T-ALL.
At present it is unclear why blasts with a NSR phenotype should respond less well to intensive therapy. One might speculate, that NSR blasts are less susceptible to apoptosis compared to SR blasts. Poor outcome in groups that might be related to NSR phenotype -pro/pre/stem cell T-ALL 9, 11, 14, [17] [18] [19] and mature T-ALL with membrane CD3 expression 11, 20 -has been reported. The prognostic value of SR and NSR phenotypes is currently examined prospectively in the COALL-97 study. It will be interesting to correlate SR phenotype with drug sensitivity, which is used for risk stratification in the COALL-97 study.
In conclusion, a classification of T-ALL subgroups with differing prognoses based on immunophenotype is described. The subgroup that is best defined as selection-related (SR) is associated with a better prognosis while in the non-selectionrelated (NSR) group a higher number of events occur despite uniform high risk adjusted treatment.
